Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine: A Pan-European study.

M.A. Javed,Georg Beyer,Nha Ngoc Hoa Le,Alessio Vinci,H. Wong,Daniel H. Palmer,Robert J. Morgan,Angela Lamarca,Richard Hubner,Juan W. Valle,Salma Alam,Sumsur Chowdhury,Yuk Ting Ma,Livia Archibugi,Gabriele Capurso,Patrick Maisonneuve,Albrecht Neesse,Malin Sund,Marvin Schober,Sebastian Krug

Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine: A Pan-European study.

2017

e15774Background: Gemcitabine (GEM) based chemotherapy has been the standard of care for patients with metastatic PDAC with marginal effects on overall survival (OS). In recent years, FOLFIRINOX an...

Keywords:

Pathology
Cancer research
Chemotherapy
Adenocarcinoma
Medicine
standard of care
FOLFIRINOX
overall survival
Oncology
pan european
pancreatic ductal adenocarcinoma
Gemcitabine
Internal medicine
clinical routine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations